Chat with us, powered by LiveChat

Invasive Fungal Infection Market (Disease Type - Candidemia and Invasive Candidiasis, Intra-abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Invasive Aspergillosis, Invasive Fungal Rhinosinusitis, Mucormycosis, and Others; Drug Type - Polyenes, Amphotericin B Deoxycholate, Lipid Formulation Amphotericin B, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Invasive Fungal Infection Market (Disease Type - Candidemia and Invasive Candidiasis, Intra-abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Invasive Aspergillosis, Invasive Fungal Rhinosinusitis, Mucormycosis, and Others; Drug Type - Polyenes, Amphotericin B Deoxycholate, Lipid Formulation Amphotericin B, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR0397 Category: Healthcare & Medical Devices Published: November, 2023

A recent report published by Infinium Global Research on invasive fungal infection market provides in-depth analysis of segments and sub-segments in the global as well as regional invasive fungal infection market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional invasive fungal infection market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global invasive fungal infection market.

Market Insight:

The global invasive fungal infection market was valued at USD 6.61 billion in 2022 and is expected to reach USD 9.06 billion in 2030, with a CAGR of 4.04% during the forecast period 2023-2030.

The invasive fungal infection market refers to the sector within the pharmaceutical and healthcare industries that focuses on diagnosing, treating, and preventing severe fungal infections that infiltrate deep into the body. These infections, which often affect individuals with compromised immune systems, can be life-threatening if not promptly addressed. The market comprises pharmaceutical companies developing antifungal medications, diagnostic tools, and treatment protocols tailored to combat these severe infections. Advancements in research, innovative drug development, and improved diagnostic techniques contribute to the expansion and evolution of this market, aiming to provide more effective solutions to address these critical medical conditions and improve patient outcomes.

The invasive fungal infection market is driven by the increasing number of immunocompromised patients. The rising number of individuals with weak immune systems due to factors such as HIV/AIDS, organ transplants, chemotherapy, and other medical conditions, significantly contributes to the growing prevalence of invasive fungal infections. This demographic requires advanced antifungal therapies, thereby driving the demand for innovative treatments and medications in the market. Moreover, advancements in medical technology and diagnostics fuel the market growth. Continuous advancements in medical technology, including more accurate diagnostic tools for early detection of fungal infections, contribute to improved patient outcomes. Enhanced diagnostics enable timely and precise identification of fungal infections, allowing for targeted treatments, leading to increased demand for antifungal medications and therapies to address the expanding market for invasive fungal infections. However, the complexity of developing new antifungal therapies can act as a barrier to market growth. Furthermore, the continuous evolution of antifungal therapies, and treatment strategies, presents a promising opportunity for the invasive fungal infection market.

Invasive Fungal Infection Market Size, Share, Trends | IGR

North America holds the largest market share in the global invasive fungal infection market. The region benefits from heightened public awareness about invasive fungal diseases, leading to increased vigilance and early diagnosis of these conditions. The Centers for Disease Control and Prevention's acknowledgment of the substantial morbidity and mortality caused by invasive fungal disorders has amplified public health initiatives and educational programs, contributing to a more informed populace in North America. This proactive awareness and understanding among people about such fungal diseases have significantly propelled the growth of the invasive fungal infection market in the region, creating a conducive environment for advancements in diagnosis and treatment. Moreover, the Asia Pacific anticipates the fastest growing region in the invasive fungal infection market due to several factors including a higher prevalence of fungal diseases, increased government support, and initiatives such as Public-private Partnerships (PPPs) in countries such as India. The Indian government's response to the surge in fungal infection cases through such collaborative strategies is significantly shaping the growth landscape of the invasive fungal infection market in India and across the broader Asia Pacific region.

Report Scope of the Invasive Fungal Infection Market:

Report Coverage Details
Market Size in 2022 USD 6.61 Billion
Market Size by 2030 USD 9.06 Billion
Growth Rate from 2023 to 2030 CAGR of 4.04%
Largest Market North America
No. of Pages 180
Market Drivers
  • The invasive fungal infection market is driven by the increasing incidence of immunocompromised patients.

  • Rapid advancements in medical technology and diagnostics fuel the market growth.

Market Segmentation By Disease Type, and By Drug Type
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global invasive fungal infection market covers segments such as disease type, and drug type. On the basis of disease type, the sub-markets include candidemia and invasive candidiasis, intra-abdominal candidiasis, cryptococcal meningitis, esophageal candidiasis, histoplasmosis acute pulmonary, invasive aspergillosis, invasive fungal rhinosinusitis, mucormycosis, and others. On the basis of drug type, the sub-markets include polyenes, amphotericin B deoxycholate, lipid formulation amphotericin B, and others.

The report provides profiles of the companies in the market such as Cidara, Basilea Pharmaceutica Ltd., Pfizer Inc., GSK plc, Bayer AG, BIOSERGEN, Merck & Co., Inc., Astellas Pharma Inc., SCYNEXIS, Inc., Cidara Therapeutics, Inc., and F2G.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the invasive fungal infection market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global invasive fungal infection market was valued at USD 6.61 Billion in 2022.
It is likely to grow at a CAGR of 4.04% during the forecast period 2023-2030.
The global invasive fungal infection market is estimated to reach USD 9.06 Billion by the end of 2030.
North America is anticipated to exhibit high demand for invasive fungal infection market during the forecast period.
Basilea Pharmaceutica Ltd., Pfizer Inc., GSK plc., Bayer AG, BIOSERGEN, Merck & Co., Inc., Astellas Pharma Inc., SCYNEXIS, Inc., Cidara Therapeutics, Inc., and F2G.
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.